CymaBay Therapeutics is a pioneering biopharmaceutical company dedicated to transforming the lives of individuals suffering from chronic liver, digestive tract, or inflammatory diseases. Through innovative medicines that target the underlying causes of these conditions, CymaBay aims to restore health and improve the quality of life for patients.
Driven by a deep commitment to patients, CymaBay's lead compound, seladelpar, shows promise in reducing symptoms and slowing the progression of liver, metabolic, and inflammatory diseases. Supported by an extensive development program, CymaBay's unique approach to research is changing lives and advancing the standard of care in the field of medicine.
Generated from the website